Company intelligence / Profile preview

Proto Pharma Ltd

Ownership: Private
Development stage: Other

Overview

Proto Pharma Ltd has developed and commercialized artemether, an antimalarial drug targeting the ATP2A1 x SERCA2 protein. Artemether is approved in China and has been evaluated in at least one completed Phase 3 trial comparing its ArTiMist™ formulation to intravenous quinine for severe or complicated falciparum malaria in children. The company appears to focus on translational medicine and collaborates with academic institutions such as Fudan University and the Shanghai Institute of Materia Medica.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ArTiMist

Beyond the preview

Go deeper on Proto Pharma Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proto Pharma Ltd.

Explore the full profile